$Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient$

Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Seizure (London, England) England), 2020-08, Vol.80, p.157-158
Hauptverfasser:	Gómez-Enjuto, Sara, Hernando-Requejo, Virgilio, Lapeña-Motilva, José, Ogando-Durán, Gonzalo, Fouz-Ruiz, Daniel, Domingo-García, Julio, Rodríguez-García, Elena, Cemillán-Fernández, Carlos Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anemia - etiology Anticoagulants - therapeutic use Anticonvulsants - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus Calcium Channel Blockers - therapeutic use Clinical Neurology Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronavirus Infections - physiopathology COVID-19 Drug Combinations Enzyme Inhibitors - therapeutic use Humans Hydroxychloroquine - therapeutic use Life Sciences & Biomedicine Lopinavir - therapeutic use Lymphopenia - etiology Male Neurosciences Neurosciences & Neurology Pandemics Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pneumonia, Viral - physiopathology Posterior Leukoencephalopathy Syndrome - diagnostic imaging Posterior Leukoencephalopathy Syndrome - etiology Posterior Leukoencephalopathy Syndrome - physiopathology PRES Ritonavir - therapeutic use SARS-CoV-2 Science & Technology Status epilepticus Status Epilepticus - drug therapy Status Epilepticus - etiology Verapamil Verapamil - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!